Press Releases
Wren is taking a transformative approach to drug discovery, targeting the fleeting intermediates that are central to many disease pathways but have been beyond the reach of conventional drug discovery approaches.
Our first focus is on two of the most prominent unmet medical needs of our time: Neurodegeneration in Alzheimer's disease and Parkinson’s disease.
-
Press Releases | Mar 2022
Wren Appoints Bart Henderson as Chief Executive Officer
-
Press Releases | Jan 2021
Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million)
-
Press Releases | Nov 2020
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies